ABSI Reports Positive Phase 1 Data
Absci announces positive interim phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor
ABSI - Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)